Jazz Pharmaceuticals (JAZZ)

Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

The U.S. Food and Drug Administration said on Wednesday that it has approved Jazz Pharmaceuticals' drug to treat diffuse midline glioma, a rare and aggressive tumor, in adults and children aged one ye...

Jazz shares slide as Q2 loss widens on Chimerix charge, with 2025 sales outlook trimmed despite higher EPS guidance.

Jazz (JAZZ) Q2 Revenue Rises 2%

Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Bruce C. Cozadd - Co-Founder, Chairman & CEO Jack Spinks - Corporate Participant...

While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wa...

Jazz Pharmaceuticals (JAZZ) came out with a quarterly loss of $8.25 per share versus the Zacks Consensus Estimate of a loss of $6.12. This compares to earnings of $5.3 per share a year ago.

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jazz Pharmaceuticals (NASDAQ: JAZZ) is currently trading at approximately $110, having decreased by 11% year-to-date, even after a significant positive development with the conditional European Commis...

In recent months, Jazz Pharmaceuticals plc has remained a stock that has seen some decline in attention from retail investors. This comes amid the potential approval of Zepzelca in combination with Te...